Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. [...]

Recent molecular characterization of primary urothelial carcinoma (UC) may guidefuture clinical decision-making. For metastatic UC (mUC), a comprehensive molecularcharacterization is still lacking. [...]

Background: A comprehensive assessment of biopsies from metastatic prostate cancer (mPCa) patients (pts) may identify a molecular subset of pts susceptible for immune checkpoint (IC) blockade (ICB).Methods: 148 biopsies and germline DNA from 145 mPCa pts were whole genome sequenced (WGS) at an average of 114x and 38x. Tumour mutational (mut) burden (TMB) was defined as number of somatic single nucleotide variants and InDels per Mb of the genome, known mut signatures (Alexandrov, Nature 2013) extracted by non-negative least squares regression as well as recurrent mutations reported in mismatch repair (MMR) pts (Kim, Cell 2013). [...]

For individual treatment decisions in patients with metastatic prostate cancer (mPC), molecular diagnostics are increasingly used. Bone metastases are frequently the only source for obtaining metastatic tumor tissue. [...]

Metastatic castration-resistant prostate cancer (mCRPC) has a highly complex genomiclandscape. With the recent development of novel treatments, accurate stratification strategies are needed. [...]